Research programme: chimeric antigen receptor monocytes - Carisma Therapeutics/University of Pennsylvania
Alternative Names: Anti-HER2 CAR monocytes - Carisma Therapeutics/University of Pennsylvania; CAR-Mono - Carisma Therapeutics/University of PennsylvaniaLatest Information Update: 28 Jun 2024
At a glance
- Originator University of Pennsylvania
- Developer Carisma Therapeutics; University of Pennsylvania
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV, Infusion)
- 08 Apr 2022 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 22 Jun 2020 Pharmacodynamics data from a preclinical trial in Cancer presented at the 111th Annual Meeting of the American Association for Cancer Research (AACR-2020)